BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. One Stock Could Have the Edge for 2027

BioNTech and Moderna are transitioning from pandemic-era COVID-19 vaccine dominance to sustainable businesses through oncology and other disease pipelines. BioNTech is favored for 2027 due to its stronger financial position (€16.2 billion cash, zero debt, positive cash flow) and expanding cancer treatment pipeline, while Moderna faces greater financial pressure from declining vaccine revenue despite promising late-stage cancer vaccine results.

11/09/2026, 5:00 AM • The Motley Fool

Decoding Healthcare ETFs: Different Sectors, Different Strategies

The article compares two healthcare ETFs: RSPH (Invesco S&P 500 Equal Weight Healthcare ETF) and XBI (State Street SPDR S&P Biotech ETF). RSPH offers broader healthcare sector diversification with lower volatility and higher dividend yield (0.56%), while XBI provides concentrated biotech exposure with higher short-term returns (39.6% 1-year) but steeper drawdowns (53.2% max). RSPH is recommended for conservative investors seeking stability, while XBI suits those with higher risk tolerance seeking biotech-specific growth.

11/07/2026, 10:15 AM • The Motley Fool

Bristol Myers Squibb vs. Vertex: Which Pharma Stock Is a Better Buy for 2027?

The article compares Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX) as investment options for 2027. BMY trades at a cheaper valuation (9.8x forward P/E) with a 4.06% dividend yield but faces revenue concentration risks and uncertain recovery timeline. VRTX commands a higher valuation (29.8x forward P/E) but demonstrates superior growth prospects, strong margins (85.61%), and successful product launches like Alyftrek. The author recommends Vertex as the better choice, citing its strong execution and growth momentum despite higher valuation multiples.

11/07/2026, 9:37 AM • The Motley Fool

Moderna Just Gave Investors Yet Another Thing to Cheer About

Moderna reported a surprise profitable quarter with $1.31B in revenue (29% YoY growth) and $0.38 EPS, defying analyst expectations of a loss. The company raised full-year guidance and ended with $8.1-8.3B in cash. Its cancer vaccine with Merck showed strong Phase 3 results, reducing melanoma recurrence risk by 42%, while the stock has surged 720% in 2026. However, risks include COVID vaccine sales volatility and significant optimism already priced into the stock.

11/06/2026, 9:48 AM • The Motley Fool

Could Investing in Moderna's Stock Double Your Money?

Moderna's stock has surged over 650% in 2026 driven by excitement around its cancer vaccine intismeran, developed with Merck. While the vaccine shows promising clinical trial results for melanoma and is being evaluated for other cancers, it remains unapproved. Despite this year's gains, the stock is still down 36% over five years. For the stock to double to a $180 billion valuation, Moderna would need strong revenue generation beyond expectations, making it a high-risk investment.

11/03/2026, 5:08 AM • The Motley Fool

Amgen Just Gave Its Shareholders Great News

Amgen's cancer drug Imdelltra demonstrated significant efficacy when combined with AstraZeneca's Imfinzi, reducing death risk by 58% in advanced lung cancer patients and extending median survival to 21.1 months versus 12.7 months with Imfinzi alone. With Imdelltra already generating 115% growth and a robust pipeline of 22 double-digit growth products, Amgen's stock may have further upside potential despite its 40% year-to-date gain.

11/02/2026, 12:25 PM • The Motley Fool

If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started

Moderna's stock has surged 650% in 2026, driven by excitement around its cancer vaccine intismeran developed with Merck. Recent trials showed the vaccine reduced melanoma death/recurrence risk by 42% when combined with Merck's Keytruda. CEO Stéphane Bancel believes intismeran could work across multiple cancer types where Keytruda is effective, potentially unlocking significant growth. However, the stock faces sky-high expectations and intismeran remains unapproved, warranting cautious investor approach.

11/02/2026, 9:19 AM • The Motley Fool

Breakfast News: We’re Right There With You

The Nasdaq-100 fell nearly 5% on Friday, marking its third 10% correction this year, though it has nearly doubled over three years. The article advises investors to stay invested during market volatility through strategies like dollar-cost averaging and diversification. Key earnings this week include Apple, Shopify, AMD, and Berkshire Hathaway. Kiniksa Pharmaceuticals' heart drug Arcalyst is projected to become a blockbuster with $1B+ sales. Investors should focus on long-term plans rather than election-driven trading.

11/02/2026, 7:30 AM • The Motley Fool

Stock Split Watch: Is Moderna Next?

Moderna's stock has surged 650% in 2026 following a turnaround driven by cost-cutting and focus on oncology and rare disease candidates. While the biotech's personalized cancer vaccine shows promise with strong phase 3 melanoma trial results, the article suggests a stock split may not be imminent, as the current price remains accessible to investors and the company has significant growth catalysts ahead.

11/02/2026, 3:55 AM • The Motley Fool

Will Moderna Soar on Nov. 6?

Moderna stock has surged over 100% this year, driven by positive results from its personalized cancer vaccine candidate in combination with Merck's Keytruda. The company is scheduled to report Q3 earnings on Nov. 6, with investors focused on oncology progress and cancer vaccine development. While recent data leak caused a stock dip, the author expects the next major catalyst to come from fresh cancer vaccine data rather than the earnings report itself.

10/29/2026, 4:10 AM • The Motley Fool

Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility

Axsome Therapeutics has demonstrated steady quarter-over-quarter revenue growth, surpassing Moderna's quarterly revenue by Q2 2026 despite starting from a much smaller base. Meanwhile, Moderna has experienced significant revenue volatility, with sharp declines following peaks, largely due to reduced COVID-19 vaccine adoption and underperforming RSV vaccine sales. Axsome's three-drug portfolio shows promise with multiple clinical trials underway, while Moderna faces challenges from overreliance on products that have lost market traction.

10/28/2026, 9:24 AM • The Motley Fool

Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy?

RSPH (Invesco S&P 500 Equal Weight Health Care ETF) and IBB (iShares Biotechnology ETF) offer different approaches to healthcare investing. RSPH provides broader, equal-weighted healthcare exposure with lower volatility, higher dividend yield (0.6%), and a lower expense ratio (0.4%), making it suitable for risk-averse investors. IBB offers concentrated biotech exposure with stronger recent returns (35.5% vs 31.9%) but higher volatility and drawdown risk. The choice depends on investor risk tolerance and conviction in biotechnology's momentum.

10/26/2026, 9:53 AM • The Motley Fool

Breakfast News: Science Strikes Back at Cancer

Cancer treatment breakthroughs dominate ESMO 2026 conference with multiple drugs showing significant survival gains. U.S. stocks declined amid AI spending concerns and rising oil prices, with the Fed expected to hold rates steady Wednesday. Several Motley Fool-recommended companies report earnings this week including Alphabet, Amazon, and Mastercard. TransDigm's stock decline reflects valuation compression rather than business deterioration.

10/26/2026, 7:30 AM • The Motley Fool

VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH), which concentrates on 25 biotech companies with higher volatility, and Invesco S&P 500 Equal Weight Health Care ETF (RSPH), which diversifies across 61 healthcare companies. While BBH showed stronger 1-year returns (38.3% vs 25.7%), RSPH is recommended for long-term investors due to lower concentration risk, broader diversification, and higher dividend yield, despite slightly higher expense ratios.

10/25/2026, 5:20 AM • The Motley Fool

Breakfast News: A Conversation With Moderna’s CEO

Moderna's CEO Stéphane Bancel discusses the company's mRNA platform technology and its personalized cancer vaccine intismeran, which showed promising phase 3 trial results for melanoma when combined with Merck's Keytruda. The CEO emphasizes Moderna's platform approach, high clinical trial success rate (85% vs. 10% industry average), patent strategy, and long-term investment focus over quarterly earnings. He also revealed buying company stock at $29 during the COVID sales decline, demonstrating confidence in the company's future pipeline including rare genetic diseases and autoimmune treatments.

10/24/2026, 7:30 AM • The Motley Fool